Cybin Inc. to Transfer U.S. Stock Listing to Nasdaq and Change Ticker Symbol

Cybin Inc. announced its decision to voluntarily transfer its U.S. stock exchange listing from NYSE American to the Nasdaq Global Market. The company expects this change to be effective by January 5, 2026, after which it will trade under the new ticker symbol "HELP". Concurrently, Cybin Inc. will begin operating under the name Helus Pharma. The company will maintain its listing on Cboe Canada, also under the "HELP" ticker symbol. This strategic move aims to align Cybin with other global pharmaceutical companies listed on Nasdaq and signifies a step in its evolution. Cybin Inc. is a clinical-stage pharmaceutical company focused on developing innovative mental healthcare treatments, with ongoing Phase 3 studies for its CYB003 and Phase 2 studies for CYB004. The company is committed to advancing its drug discovery platforms and treatment regimens for mental health conditions.